Levine Cancer Institute
Welcome,         Profile    Billing    Logout  
 2 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mahtani, Reshma
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
11/26
05/28
NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Recruiting
2
40
US
Sacituzumab Govitecan, Trodelvy, Trastuzumab, Herceptin, Trastuzumab and Hyaluronidase-oysk, Herceptin Hylecta
Adrienne G. Waks, Gilead Sciences
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
11/26
11/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Terminated
2
52
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer
Breast Cancer, Triple Negative Breast Cancer
10/24
12/24
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Recruiting
1/2
52
US
Evexomostat, SDX-7320
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
03/26
09/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Fernandez, Krystal
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
Rader, Ryan
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
LoTam, NCT06671912: Testing Low Dose Tamoxifen for Invasive Breast Cancer, the () Trial

Recruiting
3
1156
US
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
11/30
11/31
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mahtani, Reshma
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
11/26
05/28
NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Recruiting
2
40
US
Sacituzumab Govitecan, Trodelvy, Trastuzumab, Herceptin, Trastuzumab and Hyaluronidase-oysk, Herceptin Hylecta
Adrienne G. Waks, Gilead Sciences
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
11/26
11/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Terminated
2
52
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer
Breast Cancer, Triple Negative Breast Cancer
10/24
12/24
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Recruiting
1/2
52
US
Evexomostat, SDX-7320
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
03/26
09/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Fernandez, Krystal
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
Rader, Ryan
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
LoTam, NCT06671912: Testing Low Dose Tamoxifen for Invasive Breast Cancer, the () Trial

Recruiting
3
1156
US
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
11/30
11/31

Download Options